Less Ads, More Data, More Tools Register for FREE

Pin to quick picksHikma Pharmaceuticals Regulatory News (HIK)

Share Price Information for Hikma Pharmaceuticals (HIK)

Share Price is delayed by 15 minutes
Get Live Data
1,462.00    -5.00 (-0.34%)
Bid:
1,468.00
Ask:
1,469.00
Spread: 1.00 (0.068%)
Market Cap: £3.09b
HIK Live PriceLast checked at - London Stock Exchange

Intraday Hikma Pharmaceuticals Share Chart

Director/PDMR Shareholding

10 Apr 2018 14:34

RNS Number : 4612K
Hikma Pharmaceuticals Plc
10 April 2018
Β 

Β 

Hikma Pharmaceuticals PLC - EIP Awards

LONDON, 10 April 2018: Hikma Pharmaceuticals PLC (LSE: HIK) (NasdaqDubai: HIK) ("Hikma") (LEI: 549300BNS685UXH4JI75) announces that the following Persons Discharging Managerial Responsibility ("PDMR") have received shares as a result of the vesting of their conditional share awards on 10 April 2015 under the 2014 Executive Incentive Plan ("EIP") which was completed on10 April 2018. These awards were automatically exercised by operation of the conditional award and vesting process. The exercise price under the EIP is Β£nil.

Notification and public disclosure of transactions by persons discharging managerial responsibilities

Bassam Kanaan

1

Details of the person discharging managerial responsibilities / person closely associated

a)

Name

Bassam Kanaan

2

Reason for the notification

a)

Position/status

PDMR

b)

Initial notification /Amendment

Initial notification

3

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

Hikma Pharmaceuticals PLC

b)

LEI

549300BNS685UXH4JI75

4

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument, type of instrument and identification code

Description: Ordinary shares of 10 pence each (Shares)

ID Code: GB00B0LCW083

b)

Nature of the transaction

Β 

Shares acquired from vesting of the conditional awards on10 April 2018 under the EIP.

c)

Price(s) and volume(s)

Price(s): Β£nil

Volume(s): 19,945

d)

Aggregated information

N/A

e)

Date of the transaction

10 April 2018

f)

Place of the transaction

London Stock Exchange (XLON)

Β 

Khalid Nabilsi

1

Details of the person discharging managerial responsibilities / person closely associated

a)

Name

Khalid Nabilsi

2

Reason for the notification

a)

Position/status

PDMR

b)

Initial notification /Amendment

Initial notification

3

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

Hikma Pharmaceuticals PLC

b)

LEI

549300BNS685UXH4JI75

4

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument, type of instrument and identification code

Description: Ordinary shares of 10 pence each (Shares)

ID Code: GB00B0LCW083

b)

Nature of the transaction

Β 

Shares acquired from vesting of the conditional awards on10 April 2018 under the EIP.

c)

Price(s) and volume(s)

Price(s): Β£nil

Volume(s): 14,165

d)

Aggregated information

N/A

e)

Date of the transaction

10 April 2018

f)

Place of the transaction

London Stock Exchange (XLON)

Riad Mishlawi

1

Details of the person discharging managerial responsibilities / person closely associated

a)

Name

Riad Mishlawi

2

Reason for the notification

a)

Position/status

PDMR

b)

Initial notification /Amendment

Initial notification

3

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

Hikma Pharmaceuticals PLC

b)

LEI

549300BNS685UXH4JI75

4

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument, type of instrument and identification code

Description: Ordinary shares of 10 pence each (Shares)

ID Code: GB00B0LCW083

b)

Nature of the transaction

Β 

Shares acquired from vesting of the conditional awards on10 April 2018 under the EIP.

c)

Price(s) and volume(s)

Price(s): Β£nil

Volume(s): 13,811

d)

Aggregated information

N/A

e)

Date of the transaction

10 April 2018

f)

Place of the transaction

London Stock Exchange (XLON)

Β 

Β 

Majda Labadi

1

Details of the person discharging managerial responsibilities / person closely associated

a)

Name

Majda Labadi

2

Reason for the notification

a)

Position/status

PDMR

b)

Initial notification /Amendment

Initial notification

3

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

Hikma Pharmaceuticals PLC

b)

LEI

549300BNS685UXH4JI75

4

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument, type of instrument and identification code

Description: Ordinary shares of 10 pence each (Shares)

ID Code: GB00B0LCW083

b)

Nature of the transaction

Β 

Shares acquired from vesting of the conditional awards on10 April 2018 under the EIP.

c)

Price(s) and volume(s)

Price(s): Β£nil

Volume(s): 10,089

d)

Aggregated information

N/A

e)

Date of the transaction

10 April 2018

f)

Place of the transaction

London Stock Exchange (XLON)

Β 

Peter SpeirsCompany Secretary, responsible for releasing this announcement+44 (0) 20 7399 2760

This information is provided by RNS
The company news service from the London Stock Exchange
Β 
END
Β 
Β 
DSHBXGDSXXBBGIG
Date   Source Headline
25th Sep 201711:27 amRNSHolding(s) in Company
14th Sep 20173:52 pmRNSHolding(s) in Company
25th Aug 20178:41 amRNSHolding(s) in Company
17th Aug 20177:00 amRNSHikma announces licensing agreement with Takeda
17th Aug 20177:00 amRNSHalf-year Report
10th Aug 201710:05 amRNSDirector/PDMR Shareholding
10th Aug 201710:02 amRNSDirector/PDMR Shareholding
9th Aug 20179:54 amRNSDirector/PDMR Shareholding
4th Aug 20179:56 amRNSHolding(s) in Company
3rd Aug 20172:22 pmRNSNotice of Results
24th Jul 201710:53 amRNSHolding(s) in Company
4th Jul 201711:02 amRNSTotal Voting Rights
3rd Jul 20173:03 pmRNSHolding(s) in Company
30th Jun 20174:11 pmRNSHolding(s) in Company
26th Jun 20177:00 amRNSLeadership and Structural Changes to US Business
12th Jun 20174:31 pmRNSDirector/PDMR Shareholding
2nd Jun 20174:51 pmRNSTotal Voting Rights
31st May 20179:38 amRNSDirector/PDMR Shareholding
19th May 20172:44 pmRNSResult of AGM
19th May 20177:00 amRNSTrading Statement
15th May 20173:30 pmRNSDirector/PDMR Shareholding
11th May 20177:50 amRNSHikma update on ANDA for generic Advair Diskus
8th May 20179:23 amRNSChange of Registered Address
3rd May 20175:23 pmRNSTotal Voting Rights
3rd May 201710:37 amRNSChange of Registered Office
28th Apr 20172:30 pmRNSDirector/PDMR Shareholding
28th Apr 20171:57 pmRNSDirector/PDMR Shareholding
24th Apr 20173:35 pmRNSDirector/PDMR Shareholding
13th Apr 20178:58 amRNSDirector/PDMR Shareholding
13th Apr 20178:43 amRNSDirector/PDMR Shareholding
13th Apr 20178:42 amRNSDirector/PDMR Shareholding
13th Apr 20178:41 amRNSDirector/PDMR Shareholding
13th Apr 20178:36 amRNSDirector/PDMR Shareholding
11th Apr 20174:01 pmRNSDirector/PDMR Shareholding
7th Apr 201711:55 amRNSAnnual Financial Report
6th Apr 20177:00 amRNSHikma enters into settlement agreement with Jazz
3rd Apr 20173:59 pmRNSTotal Voting Rights
3rd Apr 20173:56 pmRNSBlock listing Interim Review
27th Mar 201711:13 amRNSHolding(s) in Company
23rd Mar 20179:30 amRNSDirector/PDMR Shareholding
15th Mar 20177:00 amRNSFinal Results
10th Mar 20177:30 amRNSHikma launches Desvenlafaxine Succinate Tablets
8th Mar 20174:01 pmRNSNotice of Results
8th Mar 20171:30 pmRNSDirector/PDMR Shareholding
1st Mar 20172:38 pmRNSTotal Voting Rights
13th Feb 20179:19 amRNSLicensing agreement with Orion for Easyhaler®
6th Feb 20172:27 pmRNSTotal Voting Rights
6th Feb 201712:47 pmRNSHolding(s) in Company
18th Jan 20179:11 amRNSHikma receives approval for Sodium Oxybate
20th Dec 20163:24 pmRNSDirector/PDMR Shareholding

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.